Burning Mouth Syndrome – Page 2

FDA to Reassess Use of PD-1 Inhibitors in Stomach Cancer, Seeking Expert Input on Merck, BMS, and BeiGene Medications

1 year ago talkbio0Tagged BeiGene, BMS, Burning Mouth Syndrome, Gene Expression, inhibitors, Merck, Oncologic, PD-L1, PD-L1, PDCD1 gene, United States Food and Drug Administration

FDA, PD-1 inhibitors, stomach cancer, Merck, BMS, BeiGene, Oncologic Drugs Advisory Committee, PD-L1 expression

Biotech Roundup: Compugen, Nxera Milestone Payments; Insmed Seeks $650M Offering

1 year ago talkbio0Tagged AstraZeneca, Bio, BMS, Breyanzi, Burning Mouth Syndrome, Celcuity, Compugen, K-ras Oncogene, luteolin-7-O-diglucuronide 4'-O-glucuronosyltransferase activity, milestone payments, Nordisk, Novartis, Nxera, United States Food and Drug Administration

Compugen, Nxera, milestone payments, Insmed, $650M offering, biotech, pharmaceuticals, Celcuity, Weave Bio, AstraZeneca, Novo Nordisk Foundation, FDA, LDT rule, BMS, Breyanzi, KRAS drug, Novartis

BMS Collaborates to Revolutionize Immunotherapy: The Repertoire Vaccine Partnership

1 year ago talkbio0Tagged Bristol Myers Squibb, Burning Mouth Syndrome, Cancer Therapeutic Procedure, immune system reset, Immunotherapy, Partnership, Precision Medicine, Repertoire, Vaccines

BMS, Bristol-Myers Squibb, Repertoire, immunotherapy, vaccine, immune system reset, partnership, cancer treatment, personalized medicine.

BMS Realigns Workforce Post-Mergers and Acquisitions: A Strategic Move Affecting 2,200 Employees

1 year ago talkbio0Tagged Acquisitions, Burning Mouth Syndrome, mergers, strategic, Workers

BMS, layoffs, mergers and acquisitions, workforce realignment, strategic move, 2, 200 employees

BMS-Cellares Collaboration Spotlights U.S.-China Biopharma Rivalry

1 year ago talkbio0Tagged Biopharma, Burning Mouth Syndrome, Cancer Therapeutic Procedure, CAR-T, Cell Therapy, Cellares, Collaboration, rivalry, Tension, U.S.-China

BMS, Cellares, CAR-T, collaboration, U.S.-China tensions, biopharma rivalry, cell therapy, cancer treatment.

BMS Expands CAR-T Therapy Capabilities with Strategic $380 Million Investment in Cellares

1 year ago talkbio0Tagged Automation, Biotechnology, Burning Mouth Syndrome, Cancer Therapeutic Procedure, Capacity, CAR-T, Cell Therapy, Cellares, expansion, Investments, Manufacture, squibb

BMS, Bristol Myers Squibb, Cellares, CAR-T therapy, cell therapy, cancer treatment, biotechnology, investment, capacity expansion, manufacturing, automation.